## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL				
OMB Number:	3235-0287				
stimated average burden					
ours per respons	e 0.5				

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Print or Ty	pe Response	s)														
Name and Address of Reporting Person * Opko Health, Inc.					2. Issuer Name and Ticker or Trading Symbol Sorrento Therapeutics, Inc. [SRNE]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director  X 10% Owner				
(Last) (First) (Middle) 4400 BISCAYNE BLVD.					3. Date of Earliest Transaction (Month/Day/Year) 11/22/2013								r (give title belo		Other (specify b	pelow)
(Street) MIAMI, FL 33137			4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City)	)	(State)	(Zip)			Tal	ble I - Non-	Der	ivative S	ecurities	s Acqui	ired, Disp	osed of, or	Beneficially	Owned	
1.Title of S (Instr. 3)	nstr. 3)		Date Exec Month/Day/Year) any		2A. Deemed Execution Date, if any Month/Day/Year)		Code (Instr. 8)	v V	4. Securities Acqui (A) or Disposed of (Instr. 3, 4 and 5)  (A) or Amount (D) Pr		of (D)	Beneficia	ount of Securities cially Owned Following ed Transaction(s) 3 and 4)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common	Stock		11/22/2013				S		8,471	D 8		2,173,83	59		D	
Reminder: 1 indirectly.	Report on a s	separate line f	Table II -	Deriva	tive Seci	ıriti	es Acquire	Pers con the	sons wh tained i form dis	n this fo splays a of, or Be	orm ar a curre neficia	e not req ently valid	uired to re d OMB cor	nformation espond unl ntrol numb	ess	EC 1474 (9- 02)
1. Title of Derivative Conversion or Exercise (Instr. 3)  2.		3A. Deemed Execution Date,		4. Transaction Code (Instr. 8)		5. Number of	and Expiration Date (Month/Day/Year)		7. T Am Und Sec (Ins 4)	Amount or Number		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivati Security Direct ( or Indire	(Instr. 4)		
					Code	V	(A) (D)	LAC	7.0134010	Date		of Shares				
Repor	ting O	wners														

Daniel Communication (Addison	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Opko Health, Inc. 4400 BISCAYNE BLVD. MIAMI, FL 33137		X					

# **Signatures**

Adam Logal, Vice President-Finance, Chief Accounting Officer, and Treasurer	11/25/2013
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents the weighted average purchase price for the transactions as reported on this line. The range of prices for the transactions reported on this line was \$8.48 to (1) \$8.50. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased and sold at each separate price.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB nu	mber.